246 related articles for article (PubMed ID: 25820067)
1. Multiple factors affect immunogenicity of DNA plasmid HIV vaccines in human clinical trials.
Jin X; Morgan C; Yu X; DeRosa S; Tomaras GD; Montefiori DC; Kublin J; Corey L; Keefer MC;
Vaccine; 2015 May; 33(20):2347-53. PubMed ID: 25820067
[TBL] [Abstract][Full Text] [Related]
2. HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.
Nilsson C; Hejdeman B; Godoy-Ramirez K; Tecleab T; Scarlatti G; Bråve A; Earl PL; Stout RR; Robb ML; Shattock RJ; Biberfeld G; Sandström E; Wahren B
PLoS One; 2015; 10(6):e0131748. PubMed ID: 26121679
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.
Graham BS; Koup RA; Roederer M; Bailer RT; Enama ME; Moodie Z; Martin JE; McCluskey MM; Chakrabarti BK; Lamoreaux L; Andrews CA; Gomez PL; Mascola JR; Nabel GJ;
J Infect Dis; 2006 Dec; 194(12):1650-60. PubMed ID: 17109336
[TBL] [Abstract][Full Text] [Related]
4. Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy.
Lhomme E; Richert L; Moodie Z; Pasin C; Kalams SA; Morgan C; Self S; De Rosa SC; Thiébaut R
PLoS One; 2016; 11(4):e0152952. PubMed ID: 27124598
[TBL] [Abstract][Full Text] [Related]
5. Improvement in T helper 1-related immune responses in BALB/c mice immunized with an HIV-1 gag plasmid combined with a chimeric plasmid encoding interleukin-18 and flagellin.
Chen YL; Chen YS; Hung YC; Liu PJ; Tasi HY; Ni WF; Hseuh PT; Lin HH
Microbiol Immunol; 2015 Aug; 59(8):483-94. PubMed ID: 26094825
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine.
Catanzaro AT; Roederer M; Koup RA; Bailer RT; Enama ME; Nason MC; Martin JE; Rucker S; Andrews CA; Gomez PL; Mascola JR; Nabel GJ; Graham BS;
Vaccine; 2007 May; 25(20):4085-92. PubMed ID: 17391815
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Immunogenicity in Rhesus Macaques of Transmitted-Founder, HIV-1 Group M Consensus, and Trivalent Mosaic Envelope Vaccines Formulated as a DNA Prime, NYVAC, and Envelope Protein Boost.
Hulot SL; Korber B; Giorgi EE; Vandergrift N; Saunders KO; Balachandran H; Mach LV; Lifton MA; Pantaleo G; Tartaglia J; Phogat S; Jacobs B; Kibler K; Perdiguero B; Gomez CE; Esteban M; Rosati M; Felber BK; Pavlakis GN; Parks R; Lloyd K; Sutherland L; Scearce R; Letvin NL; Seaman MS; Alam SM; Montefiori D; Liao HX; Haynes BF; Santra S
J Virol; 2015 Jun; 89(12):6462-80. PubMed ID: 25855741
[TBL] [Abstract][Full Text] [Related]
8. Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF.
Barouch DH; Santra S; Tenner-Racz K; Racz P; Kuroda MJ; Schmitz JE; Jackson SS; Lifton MA; Freed DC; Perry HC; Davies ME; Shiver JW; Letvin NL
J Immunol; 2002 Jan; 168(2):562-8. PubMed ID: 11777947
[TBL] [Abstract][Full Text] [Related]
9. Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines.
Stone GW; Barzee S; Snarsky V; Kee K; Spina CA; Yu XF; Kornbluth RS
J Virol; 2006 Feb; 80(4):1762-72. PubMed ID: 16439533
[TBL] [Abstract][Full Text] [Related]
10. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.
Kalams SA; Parker SD; Elizaga M; Metch B; Edupuganti S; Hural J; De Rosa S; Carter DK; Rybczyk K; Frank I; Fuchs J; Koblin B; Kim DH; Joseph P; Keefer MC; Baden LR; Eldridge J; Boyer J; Sherwat A; Cardinali M; Allen M; Pensiero M; Butler C; Khan AS; Yan J; Sardesai NY; Kublin JG; Weiner DB;
J Infect Dis; 2013 Sep; 208(5):818-29. PubMed ID: 23840043
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of an HIV-1 gag DNA vaccine with or without IL-12 and/or IL-15 plasmid cytokine adjuvant in healthy, HIV-1 uninfected adults.
Kalams SA; Parker S; Jin X; Elizaga M; Metch B; Wang M; Hural J; Lubeck M; Eldridge J; Cardinali M; Blattner WA; Sobieszczyk M; Suriyanon V; Kalichman A; Weiner DB; Baden LR;
PLoS One; 2012; 7(1):e29231. PubMed ID: 22242162
[TBL] [Abstract][Full Text] [Related]
12. Co-administration of plasmid-encoded granulocyte-macrophage colony-stimulating factor increases human immunodeficiency virus-1 DNA vaccine-induced polyfunctional CD4+ T-cell responses.
Santana VC; Almeida RR; Ribeiro SP; Ferreira LC; Kalil J; Rosa DS; Cunha-Neto E
Mem Inst Oswaldo Cruz; 2015 Dec; 110(8):1010-6. PubMed ID: 26602876
[TBL] [Abstract][Full Text] [Related]
13. Multiple Approaches for Increasing the Immunogenicity of an Epitope-Based Anti-HIV Vaccine.
Rosa DS; Ribeiro SP; Fonseca SG; Almeida RR; Santana VC; Apostólico Jde S; Kalil J; Cunha-Neto E
AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1077-88. PubMed ID: 26149745
[TBL] [Abstract][Full Text] [Related]
14. HIV-1 DNA vaccine efficacy is enhanced by coadministration with plasmid encoding IFN-alpha.
Jiang W; Ren L; Jin N
J Virol Methods; 2007 Dec; 146(1-2):266-73. PubMed ID: 17868910
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide.
Huang Y; Chen A; Li X; Chen Z; Zhang W; Song Y; Gurner D; Gardiner D; Basu S; Ho DD; Tsuji M
Vaccine; 2008 Mar; 26(15):1807-16. PubMed ID: 18329757
[TBL] [Abstract][Full Text] [Related]
16. The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection.
Jacobson JM; Zheng L; Wilson CC; Tebas P; Matining RM; Egan MA; Eldridge J; Landay AL; Clifford DB; Luetkemeyer AF; Tiu J; Martinez AL; Janik J; Spitz TA; Hural J; McElrath J; Frahm N;
J Acquir Immune Defic Syndr; 2016 Feb; 71(2):163-71. PubMed ID: 26761518
[TBL] [Abstract][Full Text] [Related]
17. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice.
Shephard E; Burgers WA; Van Harmelen JH; Monroe JE; Greenhalgh T; Williamson C; Williamson AL
AIDS Res Hum Retroviruses; 2008 Feb; 24(2):207-17. PubMed ID: 18240963
[TBL] [Abstract][Full Text] [Related]
18. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.
Mpendo J; Mutua G; Nyombayire J; Ingabire R; Nanvubya A; Anzala O; Karita E; Hayes P; Kopycinski J; Dally L; Hannaman D; Egan MA; Eldridge JH; Syvertsen K; Lehrman J; Rasmussen B; Gilmour J; Cox JH; Fast PE; Schmidt C
PLoS One; 2015; 10(8):e0134287. PubMed ID: 26252526
[TBL] [Abstract][Full Text] [Related]
19. Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex.
Garzón MR; Berraondo P; Crettaz J; Ochoa L; Vera M; Lasarte JJ; Vales A; Van Rooijen N; Ruiz J; Prieto J; Zulueta J; González-Aseguinolaza G
Vaccine; 2005 Feb; 23(11):1384-92. PubMed ID: 15661387
[TBL] [Abstract][Full Text] [Related]
20. Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine.
Cheeseman HM; Day S; McFarlane LR; Fleck S; Miller A; Cole T; Sousa-Santos N; Cope A; Cizmeci D; Tolazzi M; Hwekwete E; Hannaman D; Kratochvil S; McKay PF; Chung AW; Kent SJ; Cook A; Scarlatti G; Abraham S; Combadiere B; McCormack S; Lewis DJ; Shattock RJ
Hum Gene Ther; 2018 Sep; 29(9):1011-1028. PubMed ID: 30027768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
